

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/572,418

Confirmation No.: 7910

Applicant: Asa Rosenquist, et al

Filed: January 22, 2007

TC/A.U.: 1654

Examiner: Julie Ha

Docket No.: 140309-4

Customer No.: 35684

For: Hcv ns-3 Serine Protease Inhibitors

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sirs:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the references listed on attached forms PTO/SB/08a be considered by the Examiner and made of record. Copies of cited foreign patent documents and non-patent literature documents are submitted herewith.

In accordance with 37 C.F.R. § 1.97(g) and (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, as an admission that the information cited herein is, or is considered to be, material to patentability, or that no other possible material information as defined in 37 C.F.R. § 1.56 exists.

This Information Disclosure Statement is being filed more than three months from the U.S. filing date, after the mailing date of the first Office Action on the merits, and before the mailing date of any of a final action under 37 CFR § 1.113, a notice of

allowance under 37 CFR § 1.311, or an action that otherwise closes prosecution in the application. Accordingly, the undersigned hereby authorizes the Commissioner of Patents to charge the necessary fee under 37 C.F.R. § 1.17(p) of \$180.00 to Deposit Account 12-2136, as well as any additional fees which may be due in connection with the filing of this paper.

Respectfully submitted,

Dated: March 30, 2009


Mehdi Ganjeizaden
Registration No. 47585
Butzel Long
350 S. Main Street, Ste. 300
Ann Arbor, MI 48104
Tel. (734) 213-3436
Fax (734) 995-1777